ASCO26: Abbott demonstrates MRD test benefit in TNBC recurrence

Abbott presented the data obtained from a prospective sub-study of the PARTNER trial at this year’s ASCO meeting in Chicago, Illinois. Abbott presented the data obtained from a prospective sub-study of the PARTNER trial at this year’s ASCO meeting in Chicago, Illinois. MRD testing is a growing area in cancer diagnostics. Credit: JHVEPhoto / Shutterstock.com New prospective sub-study analysis data presented by Abbott at the 2026 American Society of Clinical Oncology (ASCO) meeting has highlighted the value of minimal residual disease (MRD) testing in charting distant recurrences in triple-negative breast cancer (TNBC) patients. In a sub-study of Cambridge University Hospitals…

Source: Medical Device Network